001450:KRXHyundai Marine & Fire Insurance Co., Ltd. Analysis
Data as of 2026-03-07 - not real-time
₩30,850.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at 30,850 KRW, well below its DCF‑derived fair value of roughly 718,000 KRW, indicating a substantial valuation gap. Technical analysis shows a bullish trend direction, supported by the price staying above the 200‑day SMA (28,018) and the 50‑day SMA (30,422), while the 20‑day SMA (32,965) remains a short‑term resistance. Momentum indicators are mixed: the RSI sits at 46, suggesting neutral pressure, and the MACD histogram is negative, signaling bearish momentum in the near term. Volume is on an increasing trend, which adds confidence to the price movements and reduces short‑term liquidity concerns. The stock’s beta of 0.33 points to low systematic risk, but the 30‑day volatility of 65% signals heightened price swings. The fear‑and‑greed index at 68.77 places the market in a “greed” phase, implying investor optimism that could sustain price appreciation.
Fundamentally, Hyundai Marine & Fire Insurance delivers solid revenue growth of 8.4% and a respectable ROE of 20%, outpacing many peers in the insurance sector. Its gross margin of 19.9% and operating margin of 12.8% reflect efficient underwriting, yet free cash flow remains negative, highlighting capital‑intensive operations. The forward PE of 2.64 is dramatically lower than the industry average of 17.46, reinforcing the undervaluation narrative. With a debt‑to‑equity ratio of 72.7% and a strong cash pile exceeding 35 trillion KRW, the balance sheet is comfortable enough to weather adverse scenarios. Analyst consensus leans “buy” with a median target of 36,000 KRW, translating to an upside potential of roughly 16% from the current price. Given these dynamics, the stock presents a compelling case for investors seeking value‑oriented exposure with upside upside.
Fundamentally, Hyundai Marine & Fire Insurance delivers solid revenue growth of 8.4% and a respectable ROE of 20%, outpacing many peers in the insurance sector. Its gross margin of 19.9% and operating margin of 12.8% reflect efficient underwriting, yet free cash flow remains negative, highlighting capital‑intensive operations. The forward PE of 2.64 is dramatically lower than the industry average of 17.46, reinforcing the undervaluation narrative. With a debt‑to‑equity ratio of 72.7% and a strong cash pile exceeding 35 trillion KRW, the balance sheet is comfortable enough to weather adverse scenarios. Analyst consensus leans “buy” with a median target of 36,000 KRW, translating to an upside potential of roughly 16% from the current price. Given these dynamics, the stock presents a compelling case for investors seeking value‑oriented exposure with upside upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Mixed MACD signals indicating short‑term bearish pressure
- Price near 20‑day SMA resistance
- Increasing volume supports stability
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap vs DCF
- Strong ROE and revenue growth
- Low beta and favorable analyst outlook
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained cash reserves and manageable debt
- Industry low PE relative to peers
- Long‑term demographic tailwinds for non‑life insurance in Korea
Key Metrics & Analysis
Financial Health
Revenue Growth8.40%
Profit Margin6.58%
P/E Ratio2.6
ROE20.19%
ROA1.69%
Debt/Equity72.67
Op. Cash Flow₩1780.7B
Free Cash Flow₩-3688710799360
Industry P/E17.5
Technical Analysis
TrendBullish
RSI46.0
Support₩27,800.00
Resistance₩44,250.00
MA 20₩32,965.00
MA 50₩30,422.00
MA 200₩28,018.00
MACDBearish
VolumeIncreasing
Fear & Greed Index68.77
Valuation
Fair Value₩718,031.97
Target Price₩35,736.84
Upside/Downside15.84%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.33
Volatility65.56%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.